Literature DB >> 31580253

What are the Characteristics of Patients Experiencing Adverse Drug Reactions to Oral Anticogulants and How Can Such Reactions be Prevented?

G Spada1, G V Vighi1, S Pagani1, G D Vighi1, M Venegoni1, M Ruocco1.   

Abstract

INTRODUCTION: Oral anticoagulants, including vitamin K inhibitors (VKAs) and direct anticoagulants (DOACs) are important for preventing and treating thromboembolic diseases. However, they are not recommended for use in all patients due to negative side effects and adverse drug reactions (ADRs). Currently, there is a paucity of information about their use in real life. Therefore, the aim of this pilot study is to report on the rate of serious ADRs in oral anticoagulant users, determine patient characteristics associated with increased risk of ADRs, and identify possible management strategies for reducing risk of ADRs within a hospital setting.
METHODS: Patients admitted to the Internal Medicine Department of the Vimercate Hospital were recruited between November 1, 2015 and October 31, 2016. All patients reporting an ADR associated with anticoagulant use were selected. Demographic, clinical, and observational data were extracted from electronic hospital records, in particular, by the hospital discharge letters and other clinical records. The main outcome of the study was to evaluate the incidence of anticoagulants serious adverse drug reactions conditioning hospital admission, the percentage of preventable reactions, and the determinants of those. RESULTS AND DISCUSSION: Of the 2,064 admissions, 102 (4.9%) eligible patients were identified. Age ranged from 60-95 years (mean = 81.9, standard deviation = 6,59) and 47.1% (n=48) were female. Of the 102 cases, 68 used VKAs and 34 used DOACs. The most common admission diagnosis was heart failure following anemia or hemorrhage (56 cases), followed by acute hemorrhage (with or without anemia; 29 cases), and anemia not associated with evident hemorrhage (17cases). The majority of VKA users (n=65, 95.6%) had a high risk of major bleeding. ADRs were found to be preventable in 96% of VKA users and 68% of DOACs users.
CONCLUSION: This study highlights the large percentage of ADRs from oral anticoagulants that can be avoided with more careful patient management. Periodic check-up of cardiac and renal function, as well as blood count, may be useful for reducing the risk of ADRs, especially in older DOACs users. Further research is needed to get new data to improve the patients monitoring system. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Oral anticoagulants; anemia; direct anticoagulants; electronic hospital records; glomerular filtrate rate; hemorrhage; vitamin K inhibitors.

Year:  2020        PMID: 31580253     DOI: 10.2174/1574886314666191003162104

Source DB:  PubMed          Journal:  Curr Drug Saf        ISSN: 1574-8863


  4 in total

1.  Cutaneous Ulcer Caused by Apixaban Treatment Is Resolved after Replacement with Dabigatran.

Authors:  Alessandro Medoro; Daniela Passarella; Donatella Mignogna; Carola Porcile; Emanuele Foderà; Mariano Intrieri; Gennaro Raimo; Pancrazio La Floresta; Claudio Russo; Gennaro Martucci
Journal:  Medicina (Kaunas)       Date:  2022-05-23       Impact factor: 2.948

Review 2.  Modification of Cardiovascular Drugs in Advanced Heart Failure: A Narrative Review.

Authors:  Manuel Martínez-Sellés; Tomasz Grodzicki
Journal:  Front Cardiovasc Med       Date:  2022-05-23

3.  Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors-An In Vitro Study.

Authors:  Nina Haagenrud Schultz; Jawed Fareed; Pål Andre Holme
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

4.  A cell-based high-throughput screen identifies drugs that cause bleeding disorders by off-targeting the vitamin K cycle.

Authors:  Xuejie Chen; Caihong Li; Da-Yun Jin; Brian Ingram; Zhenyu Hao; Xue Bai; Darrel W Stafford; Keping Hu; Jian-Ke Tie
Journal:  Blood       Date:  2020-08-13       Impact factor: 25.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.